Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.

ABSTRACT:

Background

Currently available semiautomated insulin-delivery systems require individualized insulin regimens for the initialization of therapy and meal doses based on carbohydrate counting for routine operation. In contrast, the bionic pancreas is initialized only on the basis of body weight, makes all dose decisions and delivers insulin autonomously, and uses meal announcements without carbohydrate counting.

Methods

In this 13-week, multicenter, randomized trial, we randomly assigned in a 2:1 ratio persons at least 6 years of age with type 1 diabetes either to receive bionic pancreas treatment with insulin aspart or insulin lispro or to receive standard care (defined as any insulin-delivery method with unblinded, real-time continuous glucose monitoring). The primary outcom

SUBMITTER: Bionic Pancreas Research Group 

PROVIDER: S-EPMC10028490 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature